85 results about "Dual release" patented technology

A lipophilic vehicle-based dual controlled-release matrix, suitable for encapsulation in hard or soft capsules, has been developed. The matrix is in the form of a suspension, which allows for easier formulation of low dose compounds and / or compounds which are moisture sensitive. The matrix includes two rate controlling barriers for the controlled release of one or more pharmaceutically active agents. The primary rate controlling barrier includes a relatively lipophilic oily vehicle. The primary rate controlling barrier may further comprise or more excipients, dissolved in the lipophilic vehicle, which themselves have rate controlling properties. The secondary rate controlling barrier is a hydrogel-forming polymeric material which is dispersed in the primary rate controlling barrier. As the primary rate controlling barrier breaks down, the pharmaceutically active agent is slowly released and the surrounding aqueous media begins to percolate into the polymer matrix. This results in hydration of the polymer and subsequent formation of a hydrogel, which controls the release of the drug by diffusion through, and / or erosion of, the hydrogel. By dispersing or suspending part of the pharmaceutically active agent in the primary rate controlling vehicle, a dual release profile can be obtained. The combination of release of the drug from the lipophilic oily vehicle and release of the drug from the hydrogel allows for the modulation of drug release for up to 24 hours. This system is particularly useful for moisture sensitive drugs as the oily layer prevents water migration from the shell in to the fill.

The present invention relates to a slow-release particle comprising: a matrix having a pharmacologically active component; and a slow-release layer having a substance which forms a slow-release stratum on the matrix. The slow-release particle of the present invention not only allows control of the dual release of drugs of an effective kind but can also exhibit outstanding elution characteristics even when a small amount of coating substance is used.

Disclosed is a restraint system for a vehicle. A crewmember or occupant is interconnected to the restraint system by way of a strap. The strap has two separate and independently operable release mechanisms. The strap permits the occupant to be either manually or automatically released from the associated restraint. The restraint can be mounted within any of a variety of land, sea, air, or space based vehicles. In one non-limiting embodiment, the first release mechanism is automatically activated in response to a triggering event and the second release mechanism is manually activated by the occupant pulling on a lanyard.

A dual release oral dosage system / dosage form comprising an immediate release component / composition and a delayed release component / composition is described. Each of the immediate release component / composition and delayed release component / composition comprises one or more of doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and / or a salt thereof, and one or more of pyridoxine, a salt thereof, a metabolite thereof and / or a salt of the metabolite. The dual release oral dosage system / dosage form exhibits an improved pharmacokinetic profile relative to the current Diclectin® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting in pregnancy (NVP).

The invention discloses a time-controlled pulse sustained-release oral preparation of albuterol and a preparation method thereof. The oral preparation is composed of sustained-release microspheres containing the main drug, an immediate-release coat layer wrapped outside the microspheres, and a time-lag coat layer wrapped outside the immediate-release coat layer. The present invention uses a combination of pulse and sustained release. dual release system. The dosage form is characterized by delayed pulse release over a predetermined period of time, followed by slow release. The oral preparation can provide a rapid pulse release at a specified time lag, and then continue to release the drug slowly for a period of time, so as to achieve the effect of treatment in line with the rhythm of the disease and control symptoms within a period of time. Such treatment will have maximum patient compliance and minimal side effects.